福泰製藥VRTX
那斯達克 · USD
478.13
-14.25
(-2.89%)
收盤 03/13 03:59 (UTC+8)
盤後
478.52
+0.39
(+0.08%)
03/13 03:59 (UTC+8)
福泰製藥VRTX
478.13
-14.25
(-2.89%)
財務數據
損益表
- 24.84
- 25.18
- 26.91
- 26.46
- 27.72
- 29.12
- 27.70
- 29.65
- 30.76
- 31.90
- -0.39
- 1.38
- 6.87
- -1.67
- 4.77
- 5.05
- -4.87
- 7.02
- 3.77
- 3.69
- 營業收入(億)
- 季增長率(%)
單位：美元千元
2025/Q4 | 2025/Q3 | 2025/Q2 | 2025/Q1 | 2024/Q4 | 2024/Q3 | 2024/Q2 | 2024/Q1 | 2023/Q4 | 2023/Q3 | |
營業收入淨額 | 3,190,000 | 3,076,400 | 2,964,700 | 2,770,200 | 2,912,000 | 2,771,900 | 2,645,600 | 2,690,600 | 2,517,700 | 2,483,500 |
營業成本 | 466,000 | 414,800 | 407,500 | 363,000 | 423,400 | 392,600 | 371,900 | 342,600 | 368,000 | 318,700 |
營業毛利 | 2,724,000 | 2,661,600 | 2,557,200 | 2,407,200 | 2,488,600 | 2,379,300 | 2,273,700 | 2,348,000 | 2,149,700 | 2,164,800 |
營業費用 | 1,518,100 | 1,475,400 | 1,406,100 | 1,777,100 | 1,462,600 | 1,263,000 | 5,788,400 | - | 1,161,200 | 1,126,700 |
研發費用 | 973,700 | 977,700 | 978,400 | 979,700 | 998,700 | 875,900 | 966,600 | 789,100 | 824,600 | 810,000 |
推銷及管理費用 | 487,900 | 443,200 | 425,500 | 398,600 | 376,400 | 372,100 | 372,700 | 342,600 | 318,800 | 265,000 |
非經常性項目費用 | 56,500 | 54,500 | 2,200 | 398,800 | 87,500 | 15,000 | 4,449,100 | 76,800 | 17,800 | 51,700 |
其他營業費用 | - | - | - | - | - | - | - | - | - | - |
營業利益 | 1,205,900 | 1,186,200 | 1,151,100 | 630,100 | 1,026,000 | 1,116,300 | -3,514,700 | 1,139,500 | 988,500 | 1,038,100 |
其他收入及費用 | 128,400 | 115,900 | 135,600 | 103,300 | 113,300 | 115,300 | 133,400 | 150,000 | 169,700 | 152,000 |
利息費用 | 3,300 | 3,300 | 3,700 | 3,000 | 2,800 | 7,500 | 9,900 | 10,400 | 10,600 | 10,900 |
稅前純益 | 1,331,000 | 1,298,800 | 1,283,000 | 730,400 | 1,136,500 | 1,224,100 | -3,391,200 | 1,279,100 | 1,147,600 | 1,179,200 |
所得稅 | 139,900 | 215,900 | 250,100 | 84,100 | 223,500 | 178,700 | 202,400 | 179,500 | 178,800 | 143,900 |
稅後純益 | 1,191,100 | 1,082,900 | 1,032,900 | 646,300 | 913,000 | 1,045,400 | -3,593,600 | 1,099,600 | 968,800 | 1,035,300 |
基本每股稅後盈餘(元) | 4.69 | 4.24 | 4.02 | 2.52 | 3.55 | 4.05 | -13.92 | 4.26 | 3.76 | 4.01 |
稀釋每股稅後盈餘(元) | 4.64 | 4.20 | 3.99 | 2.49 | 3.53 | 4.05 | -13.87 | 4.21 | 3.71 | 3.97 |
基本平均股數(千股) | 253900.00 | 255600.00 | 256700.00 | 256900.00 | 257500.00 | 258000.00 | 258100.00 | 258200.00 | 257700.00 | 258000.00 |
稀釋平均股數(千股) | 256100.00 | 257600.00 | 258900.00 | 259500.00 | 260500.00 | 261000.00 | 258100.00 | 261100.00 | 260900.00 | 260600.00 |
還原基本每股稅後盈餘(元) | 4.69 | 4.24 | 4.02 | 2.52 | 3.55 | 4.05 | -13.92 | 4.26 | 3.76 | 4.01 |
還原稀釋每股稅後盈餘(元) | 4.64 | 4.20 | 3.99 | 2.49 | 3.53 | 4.05 | -13.87 | 4.21 | 3.71 | 3.97 |
還原基本平均股數(千股) | 253,900 | 255,600 | 256,700 | 256,900 | 257,500 | 258,000 | 258,100 | 258,200 | 257,700 | 258,000 |
還原稀釋平均股數(千股) | 256,100 | 257,600 | 258,900 | 259,500 | 260,500 | 261,000 | 258,100 | 261,100 | 260,900 | 260,600 |
EBITDA(千元) | 1,390,000 | 1,356,100 | 1,338,400 | 781,800 | 1,185,800 | 1,284,800 | -3,327,300 | 1,343,000 | 1,217,200 | 1,232,200 |